<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1440" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1440/" /><meta name="ncbi_pagename" content="HFE Hemochromatosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>HFE Hemochromatosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="HFE Hemochromatosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/12/06" /><meta name="citation_author" content="James C Barton" /><meta name="citation_author" content="Corwin Q Edwards" /><meta name="citation_pmid" content="20301613" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1440/" /><meta name="citation_keywords" content="Hemochromatosis Type 1" /><meta name="citation_keywords" content="HFE-Associated Hemochromatosis" /><meta name="citation_keywords" content="HFE-HH" /><meta name="citation_keywords" content="Hemochromatosis Type 1" /><meta name="citation_keywords" content="HFE-Associated Hemochromatosis" /><meta name="citation_keywords" content="Hereditary hemochromatosis protein" /><meta name="citation_keywords" content="HFE" /><meta name="citation_keywords" content="HFE Hemochromatosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="HFE Hemochromatosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="James C Barton" /><meta name="DC.Contributor" content="Corwin Q Edwards" /><meta name="DC.Date" content="2018/12/06" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1440/" /><meta name="description" content="HFE hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of HFE hemochromatosis includes:" /><meta name="og:title" content="HFE Hemochromatosis" /><meta name="og:type" content="book" /><meta name="og:description" content="HFE hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of HFE hemochromatosis includes:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1440/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hemochromatosis/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1440/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88D7B7E03FC1C1000000000629023F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1440_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1440_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gcps/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/carasil/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1440_"><span class="title" itemprop="name"><i>HFE</i> Hemochromatosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Hemochromatosis Type 1, <i>HFE</i>-Associated Hemochromatosis, HFE-HH</div><p class="contrib-group"><span itemprop="author">James C Barton</span>, MD and <span itemprop="author">Corwin Q Edwards</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1440_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1440_ai__"><div class="contrib half_rhythm"><span itemprop="author">James C Barton</span>, MD<div class="affiliation small">Southern Iron Disorders Center<br />Birmingham, Alabama<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.psi@dmnori" class="oemail">moc.psi@dmnori</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Corwin Q Edwards</span>, MD<div class="affiliation small">University of Utah School of Medicine<br />Salt Lake City, Utah<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.liami@sdrawde.niwroc" class="oemail">gro.liami@sdrawde.niwroc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 3, 2000</span>; Last Update: <span itemprop="dateModified">December 6, 2018</span>.</p><p><em>Estimated reading time: 31 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hemochromatosis.Summary" itemprop="description"><h2 id="_hemochromatosis_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>HFE</i> hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of <i>HFE</i> hemochromatosis includes:</p><ul><li class="half_rhythm"><div>Persons with clinical <i>HFE</i> hemochromatosis, in whom manifestations of end-organ damage secondary to iron overload are present;</div></li><li class="half_rhythm"><div>Individuals with biochemical <i>HFE</i> hemochromatosis, in whom transferrin-iron saturation is increased and the only evidence of iron overload is increased serum ferritin concentration; and</div></li><li class="half_rhythm"><div>Non-expressing p.Cys282Tyr homozygotes, in whom neither clinical manifestations of <i>HFE</i> hemochromatosis nor iron overload are present.</div></li></ul><p>Clinical <i>HFE</i> hemochromatosis is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and anterior pituitary gland. In untreated individuals, early symptoms include: abdominal pain, weakness, lethargy, weight loss, arthralgias, diabetes mellitus; and increased risk of cirrhosis when the serum ferritin is higher than 1,000 ng/mL. Other findings may include progressive increase in skin pigmentation, congestive heart failure, and/or arrhythmias, arthritis, and hypogonadism. Clinical <i>HFE</i> hemochromatosis is more common in men than women.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>HFE</i> hemochromatosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is established by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HFE</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>Clinical <i>HFE</i> hemochromatosis: induction treatment by phlebotomy to achieve serum ferritin concentration &#x02264;50 ng/mL.</div></li><li class="half_rhythm"><div>Biochemical <i>HFE</i> hemochromatosis: start phlebotomy when serum ferritin concentration is &#x0003e;300 ng/mL.</div></li><li class="half_rhythm"><div>Non-expressing p.Cys282Tyr homozygotes: phlebotomy is not indicated, because these individuals do not have iron overload.</div></li></ul><p><i>Prevention of secondary complications:</i> Vaccination against hepatitis A and B.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div>Clinical <i>HFE</i> hemochromatosis: Once the serum ferritin concentration is &#x02264;50 ng/mL, monitor serum ferritin concentration every three to four months. Maintain serum ferritin &#x0003c;300 ng/mL (men) and &#x0003c;200 ng/mL (women) thereafter; perform standard screening for primary liver cancer in individuals who have cirrhosis.</div></li><li class="half_rhythm"><div>Biochemical <i>HFE</i> hemochromatosis and non-expressing p.Cys282Tyr homozygotes: Begin annual measurement of serum ferritin concentration when serum ferritin concentration exceeds 300 ng/mL (men) and 200 ng/mL (women).</div></li></ul><p><i>Agents/circumstances to avoid:</i> Medicinal iron, mineral supplements, excess vitamin C, and uncooked seafood; alcohol consumption in those with hepatic involvement; and daily ingestion of more than 500 mg of supplemental ascorbic acid / vitamin C.</p><p><i>Evaluation of relatives at risk:</i> Offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to the adult sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr to allow early diagnosis and surveillance.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>HFE</i> hemochromatosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><i>Risk to sibs:</i> When both parents of a person with hemochromatosis are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HFE</i> p.Cys282Tyr variant, the risk to sibs of inheriting two <i>HFE</i> p.Cys282Tyr variants is 25%. Because the <i>HFE</i> p.Cys282Tyr <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> prevalence in persons of European origin is high (11%, or 1/9), some parents of <i>HFE</i> p.Cys282Tyr homozygotes have two abnormal <i>HFE</i> alleles. If one parent is heterozygous and the other parent <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for two abnormal <i>HFE</i> alleles, the risk to each sib of inheriting two <i>HFE</i> pathogenic alleles is 50%.</p><p><i>Risk to offspring:</i> Offspring of an individual with <i>HFE</i> hemochromatosis inherit one <i>HFE</i> p.Cys282Tyr variant from the parent with <i>HFE</i> hemochromatosis. Because the chance that the other parent is a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> for <i>HFE</i> p.Cys282Tyr is 1/9, the risk that the offspring will inherit two <i>HFE</i> p.Cys282Tyr variants is approximately 5%.</p><p><i>Prenatal testing:</i> Although prenatal testing for a pregnancy at increased risk is possible once the <i>HFE</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing is not usually performed because <i>HFE</i> hemochromatosis is an adult-onset, treatable disorder with low clinical <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div></div><div id="hemochromatosis.Diagnosis"><h2 id="_hemochromatosis_Diagnosis_">Diagnosis</h2><p>The European Association for the Study of the Liver (EASL) published clinical practice guidelines including diagnosis of <i>HFE</i> hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>]. The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis of hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>] (<a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). Experts at the 2017 Hemochromatosis International meeting published an objective and practical set of recommendations for treatment of persons with hemochromatosis and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygosity based on published scientific studies and guidelines in a form suitable for patients and other persons without medical training [<a class="bk_pop" href="#hemochromatosis.REF.adams.2018.83">Adams et al 2018</a>].</p><div id="hemochromatosis.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>HFE</i> hemochromatosis <b>should be suspected</b> in individuals with a combination of the following clinical signs of advanced iron overload, biochemical evidence of hemochromatosis, and/or family history of <i>HFE</i> hemochromatosis.</p><p><b>Clinical signs of advanced iron overload</b></p><ul><li class="half_rhythm"><div>Diabetes mellitus</div></li><li class="half_rhythm"><div>Progressive increase in skin pigmentation</div></li><li class="half_rhythm"><div>Hepatomegaly</div></li><li class="half_rhythm"><div>Hepatic cirrhosis</div></li><li class="half_rhythm"><div>Arthropathy (especially involving the metacarpophalangeal joints)</div></li><li class="half_rhythm"><div>Primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma)</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Hypogonadism (usually hypogonadotrophic)</div></li></ul><p><b>Biochemical evidence of hemochromatosis</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Elevated serum transferrin-iron saturation (TS)</b> is an early and reliable indicator of risk for iron overload in <i>HFE</i> hemochromatosis; TS is not age-related in adults and is not significantly associated with the presence or absence of clinical findings or increased serum ferritin levels.</div><div class="half_rhythm">Approximately 80% of individuals with <i>HFE</i> hemochromatosis have had a fasting serum TS of at least 60% (men) or at least 50% (women) on two or more occasions in the absence of other known causes of elevated TS.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Elevated serum ferritin concentration.</b> Serum ferritin generally increases progressively over time in individuals with untreated clinical <i>HFE</i> hemochromatosis. An elevated serum ferritin concentration alone is not specific for iron overload because serum ferritin is an acute-phase reactant and elevated serum ferritin levels may be caused by non-iron liver disorders or inflammatory or neoplastic disorders (especially when the serum TS is normal).</div><div class="half_rhythm">Commonly accepted normal serum ferritin values from the HEIRS Study are &#x0003c;300 ng/mL in men and &#x0003c;200 ng/mL in women [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">No "typical" range for serum ferritin values for persons with <i>HFE</i> hemochromatosis has been defined. Values range from subnormal to several thousands.</div></li></ul><p>An algorithm for screening for <i>HFE</i> hemochromatosis has been developed (see <a class="figpopup" href="/books/NBK1440/figure/hemochromatosis.F1/?report=objectonly" target="object" rid-figpopup="fighemochromatosisF1" rid-ob="figobhemochromatosisF1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighemochromatosisF1" co-legend-rid="figlgndhemochromatosisF1"><a href="/books/NBK1440/figure/hemochromatosis.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighemochromatosisF1" rid-ob="figobhemochromatosisF1"><img class="small-thumb" src="/books/NBK1440/bin/hemochromatosis-Image001.gif" src-large="/books/NBK1440/bin/hemochromatosis-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndhemochromatosisF1"><h4 id="hemochromatosis.F1"><a href="/books/NBK1440/figure/hemochromatosis.F1/?report=objectonly" target="object" rid-ob="figobhemochromatosisF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Algorithm for screening for <i>HFE</i> hemochromatosis using LFTs (liver function tests) and TS (transferrin saturation) Originally published in Eijkelkamp et al [2000]; reused with permission</p></div></div></div><div id="hemochromatosis.Establishing_the_Diagnos"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>HFE</i> hemochromatosis is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>HFE</i>, typically p.Cys282Tyr, by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.molecular_genetic_test/?report=objectonly" target="object" rid-figpopup="fighemochromatosisTmoleculargenetictest" rid-ob="figobhemochromatosisTmoleculargenetictest">Table 1</a>).</p><p><b>Molecular testing approaches</b> can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> analysis, <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>HFE</i> hemochromatosis is broad, individuals with the distinctive findings described in <a href="#hemochromatosis.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#hemochromatosis.Option_1">Option 1</a>), whereas those in whom the diagnosis of <i>HFE</i> hemochromatosis has not been considered are more likely to be diagnosed using genomic testing (see <a href="#hemochromatosis.Option_2">Option 2</a>).</p><div id="hemochromatosis.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of <i>HFE</i> hemochromatosis, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Targeted analysis for <i>HFE</i>
<a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.His63Asp</a> can be performed first.</div><div class="half_rhythm"><b>Note:</b> Other pathogenic variants common in some populations have been described:</div><ul><li class="half_rhythm"><div>Northern Italian: <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Glu168Ter</a> and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Trp169Ter</a> [<a class="bk_pop" href="#hemochromatosis.REF.piperno.2000.441">Piperno et al 2000</a>]</div></li><li class="half_rhythm"><div>French: <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Ser65Cys</a> [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>]</div></li><li class="half_rhythm"><div>Vietnamese: <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">c.1006+1G&#x0003e;A</a> [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>]</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>HFE</i>, followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm"><b>Note:</b>
<i>HFE</i> whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has been found to be the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the Sardinian population [<a class="bk_pop" href="#hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</a>].</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>HFE</i> and other genes of interest (see <a href="#hemochromatosis.Differential_Diagnosis">Differential Diagnosis</a>) may be used to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview.</i> (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="hemochromatosis.Option_2"><h4>Option 2</h4><p>When the diagnosis of <i>HFE</i> hemochromatosis is not considered because an individual has atypical phenotypic features, comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. Exome sequencing is most commonly used; <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="hemochromatosis.T.molecular_genetic_test" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>HFE</i> Hemochromatosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1440/table/hemochromatosis.T.molecular_genetic_test/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hemochromatosis.T.molecular_genetic_test_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HFE</i></td><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis</td><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_hemochromatosis.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hemochromatosis.TF.1.1"><p class="no_margin">See <a href="/books/NBK1440/">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hemochromatosis.TF.1.2"><p class="no_margin">See <a href="#hemochromatosis.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hemochromatosis.TF.1.3"><p class="no_margin">Individuals of European ancestry; approximately 60%-90% of individuals of European ancestry with <i>HFE</i> hemochromatosis are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for variant <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a>, 1% are homozygous for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.His63Asp</a>, and 3%-8% are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for p.Cys282Tyr / p.His63Asp [<a class="bk_pop" href="#hemochromatosis.REF.feder.1996.399">Feder et al 1996</a>, <a class="bk_pop" href="#hemochromatosis.REF.morrison.2003.627">Morrison et al 2003</a>, <a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>].</p></div></dd><dt>4. </dt><dd><div id="hemochromatosis.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="hemochromatosis.TF.1.5"><p class="no_margin">Population-specific pathogenic variants have been described, including <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Glu168Ter</a> and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Trp169Ter</a>, found with <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies of 25% and 8.4% (respectively) in individuals with hemochromatosis in two northern regions of Italy [<a class="bk_pop" href="#hemochromatosis.REF.piperno.2000.441">Piperno et al 2000</a>]. The prevalence of <i>HFE</i>
<a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Ser65Cys</a> is greatest in French populations. The <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">c.1006+1G&#x0003e;A</a> occurs in Vietnamese with and without phenotypic evidence of iron overload [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>]. <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is the most common pathogenic <i>HFE</i> allele in the Sardinian population [<a class="bk_pop" href="#hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</a>].</p></div></dd><dt>6. </dt><dd><div id="hemochromatosis.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="hemochromatosis.TF.1.7"><p class="no_margin"><i>ALU</i>-mediated <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is the most common cause of hemochromatosis in the Sardinian population [<a class="bk_pop" href="#hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="hemochromatosis.Clinical_Characteristics"><h2 id="_hemochromatosis_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hemochromatosis.Clinical_Description"><h3>Clinical Description</h3><p><i>HFE</i> hemochromatosis comprises three phenotypes:</p><ul><li class="half_rhythm"><div><a href="#hemochromatosis.Clinical_HFE_Hemochromat">Clinical <i>HFE</i> hemochromatosis</a> (individuals with end-organ damage [e.g., cirrhosis, diabetes, cardiac failure, skin hyperpigmentation] secondary to iron storage)</div></li><li class="half_rhythm"><div><a href="#hemochromatosis.Biochemical_HFE_Hemochro_1">Biochemical <i>HFE</i> hemochromatosis</a> (individuals with elevated transferrin saturation [TS], not otherwise explained) with evidence of iron overload (elevated serum ferritin concentration)</div></li><li class="half_rhythm"><div><a href="#hemochromatosis.NonExpressing_p_Cys282Ty_1">Non-expressing p.Cys282Tyr homozygotes</a> (p.Cys282Tyr homozygotes without clinical or biochemical evidence of iron overload [i.e., normal serum ferritin concentration])</div></li></ul><p>Some individuals with <i>HFE</i> hemochromatosis may be identified because they have signs and symptoms related to iron overload (i.e., clinical <i>HFE</i> hemochromatosis). Other individuals are diagnosed with <i>HFE</i> hemochromatosis before symptoms develop, either through detection of abnormal iron-related studies (i.e., biochemical <i>HFE</i> hemochromatosis) or by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> used in their evaluation as family members at risk for <i>HFE</i> hemochromatosis (expressing or non-expressing p.Cys282Tyr homozygotes).</p><p><b>The difference between clinical and biochemical <i>HFE</i> hemochromatosis</b> must be understood in the interpretation of population studies evaluating morbidity related to <i>HFE</i> hemochromatosis. Several large-scale screening studies in the general population have demonstrated that most individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> do not have clinical <i>HFE</i> hemochromatosis. A significant proportion of individuals with homozygosity for p.Cys282Tyr (especially men) have biochemical <i>HFE</i> hemochromatosis.</p><p><b>Factors influencing disease manifestation</b></p><ul><li class="half_rhythm"><div><b>Gender.</b> Among <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes, a higher proportion of men than women (28% vs 1%) have manifestations of hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.allen.2008.221">Allen et al 2008</a>].</div></li><li class="half_rhythm"><div><b>Detection through screening.</b> When identified through iron studies or screening of at-risk family members, 75%-90% of individuals with <i>HFE</i> hemochromatosis are asymptomatic.</div><ul><li class="half_rhythm"><div>Normal serum ferritin concentration at diagnosis is usually associated with lack of symptom development [<a class="bk_pop" href="#hemochromatosis.REF.yamashita.2003.388">Yamashita &#x00026; Adams 2003</a>].</div></li><li class="half_rhythm"><div>Clinical disease is more common among p.Cys282Tyr <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> sibs of clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> p.Cys282Tyr homozygotes than among p.Cys282Tyr homozygotes identified outside of family studies.</div></li></ul></li></ul><div id="hemochromatosis.Clinical_HFE_Hemochromat"><h4>Clinical <i>HFE</i> Hemochromatosis</h4><p>Individuals with clinical <i>HFE</i> hemochromatosis have inappropriately high absorption of iron from a normal diet by the mucosa of the small intestine, resulting in excessive parenchymal storage of iron, which may result in damage to target organs and, potentially, organ failure.</p><p><b>Age of onset.</b> Symptoms related to iron overload usually appear between age 40 and 60 years in men and after menopause in women. Occasionally, <i>HFE</i> hemochromatosis manifests at an earlier age, but hepatic fibrosis or cirrhosis is rare before age 40 years.</p><p><b>Early signs.</b> Often the first signs of clinical <i>HFE</i> hemochromatosis are arthropathy (joint stiffness and pain) involving the metacarpophalangeal joints, progressive increase in skin pigmentation resulting from deposits of melanin and iron, diabetes mellitus resulting from pancreatic iron deposits, and cardiomyopathy resulting from cardiac parenchymal iron stores. Hepatomegaly may or may not be present early in <i>HFE</i> hemochromatosis. Some asymptomatic individuals have hepatomegaly on physical examination. Some men, typically those with severe iron overload, have erectile dysfunction, hypotestosteronemia, loss of muscle mass, and osteoporosis due to hypogonadotrophic hypogonadism. In women, hypogonadism leads to diminished libido, amenorrhea, and infertility in some individuals. Abdominal pain, weakness, lethargy, and weight loss are common nonspecific findings [<a class="bk_pop" href="#hemochromatosis.REF.edwards.2018">Edwards &#x00026; Barton 2018</a>].</p><p>The HEIRS Study found an odds ratio of 3.3 for liver disease among men <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>]. With progressive iron overload, cirrhosis may develop and be complicated by portal hypertension, primary liver cancer, and end-stage liver disease [<a class="bk_pop" href="#hemochromatosis.REF.kowdley.2005.494">Kowdley et al 2005</a>]. Alcohol consumption worsens the symptoms in <i>HFE</i> hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.scotet.2003.129">Scotet et al 2003</a>]. Approximately 50% of individuals with cirrhosis or liver failure also have diabetes mellitus and approximately 15% have congestive heart failure or cardiac arrhythmias. Cirrhosis is more common among p.Cys282Tyr homozygotes who consume more than 60 g of alcohol per day [<a class="bk_pop" href="#hemochromatosis.REF.fletcher.2002.281">Fletcher et al 2002</a>]. Age, diabetes, alcohol consumption, and severity of iron overload increase the risk of cirrhosis, after adjusting for other factors [<a class="bk_pop" href="#hemochromatosis.REF.barton.2018.871">Barton et al 2018</a>].</p><p><b>Life expectancy.</b> Individuals diagnosed and treated prior to the development of cirrhosis have normal life expectancy. Those diagnosed after the development of cirrhosis have a decreased life expectancy even with iron depletion therapy [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>], primarily due to the development of hepatocellular cancer.</p><p><b>Prognosis.</b> Individuals with cirrhosis who are treated have a better outcome than those who are not treated. Treatment of patients with cirrhosis to achieve iron depletion does not eliminate the 10%-30% risk of primary liver cancer (e.g., hepatocellular carcinoma, cholangiocarcinoma).</p><p>Failure to deplete iron stores after 18 months of treatment is a poor prognostic sign that reflects iron overload severity in most individuals and insufficient phlebotomy therapy in other individuals. With iron depletion, dysfunction of some organs (liver and heart) can improve. Endocrine abnormalities and arthropathy improve in 20% of treated individuals.</p><p>Death in individuals with clinical <i>HFE</i> hemochromatosis is often caused by liver failure, primary liver cancer, extrahepatic cancers, congestive heart failure, or arrhythmia.</p></div><div id="hemochromatosis.Biochemical_HFE_Hemochro"><h4>Biochemical <i>HFE</i> Hemochromatosis</h4><p>It is controversial whether individuals who have biochemical <i>HFE</i> hemochromatosis in the absence of clinical <i>HFE</i> hemochromatosis are at increased risk of developing complications of iron overload and are therefore candidates for phlebotomy treatment (see <a href="#hemochromatosis.Management">Management</a>).</p><p><b>Ferritin levels at diagnosis.</b> Bardou-Jacquet and colleagues concluded that <i>HFE</i>
<a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes with a serum ferritin at diagnosis between the upper limit of normal and 1,000 &#x003bc;g/L have lower mortality than the general population due to phlebotomy therapy [<a class="bk_pop" href="#hemochromatosis.REF.bardoujacquet.2015a.1917">Bardou-Jacquet et al 2015a</a>, <a class="bk_pop" href="#hemochromatosis.REF.bardoujacquet.2015b.283">Bardou-Jacquet et al 2015b</a>, <a class="bk_pop" href="#hemochromatosis.REF.bardoujacquet.2015c.682">Bardou-Jacquet et al 2015c</a>]. Conversely, an Australian consortium concluded that the benefits of phlebotomy for p.Cys282Tyr homozygotes with mildly elevated serum ferritin remain unproven without a randomized study with long-term follow-up [<a class="bk_pop" href="#hemochromatosis.REF.delatycki.2015.282">Delatycki et al 2015</a>].</p><p>Prospective follow-up study of a few <i>HFE</i> Cys282Tyr homozygotes found that iron overload is not progressive in all individuals. Although serum ferritin concentration may rise in these individuals over time, end-organ damage is uncommon and is more frequently observed in men than women [<a class="bk_pop" href="#hemochromatosis.REF.allen.2008.221">Allen et al 2008</a>, <a class="bk_pop" href="#hemochromatosis.REF.gurrin.2008.1945">Gurrin et al 2008</a>].</p><p><b>Modifying factors.</b> It has been assumed for many years that additional modifying factors or pathogenic variants in non-<i>HFE</i> genes are required for expression of hemochromatosis in some p.Cys282Tyr homozygotes. An international consortium identified a modifying variant p.Asp519Gly in <i>GNPAT</i> in p.Cys282Tyr homozygotes, which occurs with greater frequency in men and women with severe iron overload in the absence of heavy alcohol consumption than in those without severe iron overload [<a class="bk_pop" href="#hemochromatosis.REF.mclaren.2015.429">McLaren et al 2015</a>, <a class="bk_pop" href="#hemochromatosis.REF.barton.2017.15">Barton et al 2017</a>]. <i>GNPAT</i> p.Asp519Gly was not an independent risk factor for cirrhosis in men and women with p.Cys282Tyr homozygosity who underwent liver biopsy [<a class="bk_pop" href="#hemochromatosis.REF.barton.2018.871">Barton et al 2018</a>].</p></div><div id="hemochromatosis.NonExpressing_p_Cys282Ty"><h4>Non-Expressing p.Cys282Tyr Homozygotes</h4><p>Non-expressing homozygotes are unlikely to develop end-organ damage. Women represent a higher proportion of non-expressing homozygotes than men [<a class="bk_pop" href="#hemochromatosis.REF.allen.2010.925">Allen et al 2010</a>, <a class="bk_pop" href="#hemochromatosis.REF.gan.2011.293">Gan et al 2011</a>].</p><p>Three longitudinal population-based screening studies showed that 38%-50% of p.Cys282Tyr homozygotes develop iron overload (i.e., elevated serum ferritin concentration) and 10%-33% eventually develop hemochromatosis-related symptoms [<a class="bk_pop" href="#hemochromatosis.REF.whitlock.2006.209">Whitlock et al 2006</a>] (i.e., nonspecific symptoms such as fatigue and arthralgia) or end-organ damage (e.g., cirrhosis, diabetes mellitus, and/or cardiomyopathy). The majority of <i>HFE</i> p.Cys282Tyr homozygotes who develop end-organ damage and corresponding manifestations are men [<a class="bk_pop" href="#hemochromatosis.REF.allen.2010.925">Allen et al 2010</a>, <a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>, <a class="bk_pop" href="#hemochromatosis.REF.gan.2011.293">Gan et al 2011</a>].</p></div><div id="hemochromatosis.Heterozygotes"><h4>Heterozygotes</h4><p>Some individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for either <i>HFE</i> p.Cys282Tyr or p.His63Asp have elevated serum TS and serum ferritin concentrations, but they do not develop complications of iron overload [<a class="bk_pop" href="#hemochromatosis.REF.bulaj.1996.1799">Bulaj et al 1996</a>, <a class="bk_pop" href="#hemochromatosis.REF.allen.2008.221">Allen et al 2008</a>].</p><p>Although a threshold TS of 45% may be more sensitive than higher values for detecting <i>HFE</i> hemochromatosis, TS of 45% may also identify heterozygotes who are not at risk of developing other clinical abnormalities [<a class="bk_pop" href="#hemochromatosis.REF.mclaren.1998.543">McLaren et al 1998</a>].</p><p>In a large study of Danish men, <a class="bk_pop" href="#hemochromatosis.REF.pedersen.2009.775">Pedersen &#x00026; Milman [2009]</a> showed that:</p><ul><li class="half_rhythm"><div>Among p.Cys282Tyr heterozygotes, 9% had elevated serum TS (&#x02265;50%), 9% had elevated ferritin (&#x02265;300 ng/mL), and 1.2% had elevation of both serum TS and ferritin.</div></li><li class="half_rhythm"><div>Among p.His63Asp heterozygotes, 8% had elevated serum TS, 12% had elevated ferritin, and 2% had elevation of both TS and ferritin.</div></li></ul></div></div><div id="hemochromatosis.GenotypePhenotype_Correl"><h3>Genotype-Phenotype Correlations</h3><p>Homozygotes for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> are at greater risk of developing iron overload than p.Cys282Tyr/p.His63Asp compound heterozygotes.</p></div><div id="hemochromatosis.Penetrance"><h3>Penetrance</h3><p>Penetrance of <i>HFE</i> hemochromatosis refers to the percentage of adults (men and women separately) <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for <i>HFE</i> pathogenic variants who exhibit either clinical or biochemical hemochromatosis:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant"><b>p.Cys282Tyr</b></a>
<b>homozygotes.</b> Penetrance for biochemically defined iron overload among p.Cys282Tyr homozygotes is relatively high, but not 100%. In contrast, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of clinically defined iron overload is low. Penetrance of clinical endpoints of iron overload have not been determined for individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr. Penetrance was as low as 2% in the large study by <a class="bk_pop" href="#hemochromatosis.REF.beutler.2002.211">Beutler et al [2002]</a>. Currently, no test can predict whether an individual homozygous for p.Cys282Tyr will develop clinical <i>HFE</i> hemochromatosis.</div></li><li class="half_rhythm"><div><b>p.Cys282Tyr/</b><a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant"><b>p.His63Asp</b></a>
<b>compound heterozygotes.</b> The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is low: 0.5%-2.0% of such individuals develop clinical evidence of iron overload [<a class="bk_pop" href="#hemochromatosis.REF.gurrin.2009.94">Gurrin et al 2009</a>].</div><ul><li class="half_rhythm"><div>Many p.Cys282Tyr/p.His63Asp compound heterozygotes who develop clinical evidence of iron overload have a concomitant factor (e.g., fatty liver, viral hepatitis) that may increase iron absorption, enhance liver injury, or increase TS and serum ferritin levels due to hepatocellular injury.</div></li><li class="half_rhythm"><div>Male p.Cys282Tyr/p.His63Asp compound heterozygotes in the HEIRS Study were more likely to report a history of liver disease (odds ratio 1.7, p=0.05) [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>].</div></li></ul></li><li class="half_rhythm"><div><b>p.His63Asp homozygotes.</b> The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of this <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is lower than the penetrance of the p.Cys282Tyr/p.His63Asp genotype. Although biochemically defined abnormalities may be present, clinical manifestations characteristic of iron overload are rare [<a class="bk_pop" href="#hemochromatosis.REF.gochee.2002.646">Gochee et al 2002</a>].</div></li></ul></div><div id="hemochromatosis.Nomenclature"><h3>Nomenclature</h3><p><i>HFE</i> hemochromatosis has been variably described in the past as hereditary hemochromatosis, primary hemochromatosis, genetic hemochromatosis, and bronze diabetes with cirrhosis.</p><p>After the description of other types of iron overload associated with pathogenic variants in non-<i>HFE</i> iron-related genes, <i>HFE</i> hemochromatosis was described as either <i>HFE</i> hemochromatosis or type 1 hemochromatosis. It is preferred to specify hemochromatosis according to <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>. Using the term "hereditary" for hemochromatosis of known pathogenic genotype is redundant.</p></div><div id="hemochromatosis.Prevalence"><h3>Prevalence</h3><p>Among most populations of northern European ancestry, the prevalence of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <i>HFE</i>
<a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> is 2:1,000 to 5:1,000 [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>]. In non-Hispanic whites in North America, the prevalence of p.Cys282Tyr homozygotes is 1:200 to 1:400 [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>].</p><p>Among African Americans, p.Cys282Tyr homozygotes are rare (1:6,781). The prevalence of heterozygotes is 1:775.</p><p>Among Asians, p.Cys282Tyr homozygotes are very rare (1:25,000). The prevalence of heterozygotes is 1:1,000.</p><p>Among Hispanics, the prevalence of p.Cys282Tyr homozygotes and heterozygotes is 0.027% and 3.0%, respectively.</p><p>Heterozygosity for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.His63Asp</a> is common in most populations (northern Europeans: 25%; Hispanics: 18%; African Americans: 6%; Asians: 8.5%).</p><p>Approximately one third of northern European whites are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for either p.Cys282Tyr or p.His63Asp.</p></div></div><div id="hemochromatosis.Genetically_Related_Alle"><h2 id="_hemochromatosis_Genetically_Related_Alle_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>HFE</i>.</p></div><div id="hemochromatosis.Differential_Diagnosis"><h2 id="_hemochromatosis_Differential_Diagnosis_">Differential Diagnosis</h2><p><i>HFE</i> hemochromatosis differs from <a href="#hemochromatosis.Secondary_Iron_Overload">rarer primary iron overload disorders</a> and <a href="#hemochromatosis.Secondary_Iron_Overload">secondary iron overload disorders</a>.</p><p><b>Primary iron overload disorders</b> (summarized in Table 2) are characterized by increased absorption of iron from a normal diet in subjects without severe anemia. Juvenile hereditary hemochromatosis and <i>TFR2</i>-related hereditary hemochromatosis result from hepcidin deficiency and thus the clinical manifestations of these disorders are similar to but more severe than those of hemochromatosis associated with <i>HFE</i>
<a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygosity.</p><p>Table 2. Primary Iron Overload Disorders in the Differential Diagnosis of <i>HFE</i> Hemochromatosis</p><div id="hemochromatosis.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1440/table/hemochromatosis.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hemochromatosis.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hemochromatosis.Tc_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hemochromatosis.Tc_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hemochromatosis.Tc_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_hemochromatosis.Tc_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_hemochromatosis.Tc_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_hemochromatosis.Tc_1_1_1_4" id="hd_h_hemochromatosis.Tc_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>HFE</i> Hemochromatosis</th><th headers="hd_h_hemochromatosis.Tc_1_1_1_4" id="hd_h_hemochromatosis.Tc_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>HFE</i> Hemochromatosis</th></tr></thead><tbody><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/jh/">Juvenile hereditary hemochromatosis</a></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HJV</i><br /><i>HAMP</i></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Iron accumulation in parenchymal cells</div></li><li class="half_rhythm"><div>Cirrhosis, hypogonadotrophic hypogonadism, arthropathy, osteoporosis, &#x00026; diabetes common</div></li></ul>
</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Earlier onset</div></li><li class="half_rhythm"><div>More severe clinical manifestations</div></li><li class="half_rhythm"><div>Hepatocellular cancer not reported (possibly due to short life span)</div></li></ul>
</td></tr><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tfr2/"><i>TFR2</i>-related hereditary hemochromatosis</a></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TFR2</i></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Iron accumulation in parenchymal cells</div></li><li class="half_rhythm"><div>Cirrhosis, hypogonadotrophic hypogonadism, arthropathy, osteoporosis, &#x00026; diabetes common</div></li></ul>
</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Earlier onset</div></li><li class="half_rhythm"><div>Progression similar to <i>HJV</i>, earlier than <i>HFE</i> &#x00026; juvenile hemochromatosis</div></li></ul>
</td></tr><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ferroportin-associated iron overload<br />(OMIM <a href="http://omim.org/entry/606069" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606069</a>)</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC40A1</i></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> (hepcidin resistance) subtype:
<ul><li class="half_rhythm"><div>&#x02191; TS &#x00026; serum ferritin</div></li><li class="half_rhythm"><div>Iron deposition in hepatocytes</div></li></ul>
</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> (classic) subtype:
<ul><li class="half_rhythm"><div>Anemia</div></li><li class="half_rhythm"><div>&#x02191; serum ferritin</div></li><li class="half_rhythm"><div>Normal or &#x02193; TS</div></li><li class="half_rhythm"><div>RE iron deposition</div></li><li class="half_rhythm"><div>Low tolerance to phlebotomy therapy</div></li><li class="half_rhythm"><div>Late onset</div></li></ul>
Many persons w/classic subtype have little or no liver injury.</td></tr><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/acp/">Aceruloplasminemia</a></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CP</i></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive iron deposition in liver &#x00026; pancreas causes cirrhosis &#x00026; diabetes.</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Heavy iron deposition in brain accounts for neurologic dysfunction in adults.</div></li><li class="half_rhythm"><div>Iron deposition in retina is distinctive.</div></li><li class="half_rhythm"><div>Mild iron-deficiency anemia by early adulthood; TS low</div></li><li class="half_rhythm"><div>Rare; may be more common among Japanese</div></li></ul>
</td></tr><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BMP6</i>-related iron overload<br />(OMIM <a href="http://omim.org/entry/112266" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">112266</a>)</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BMP6</i></td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Adults <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a></div></li><li class="half_rhythm"><div>&#x02191; TS &#x00026; serum ferritin</div></li><li class="half_rhythm"><div>Arthralgias in some individuals</div></li></ul>
</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Probands usually age &#x0003e;50 yrs</div></li><li class="half_rhythm"><div>Iron overload typically mild</div></li><li class="half_rhythm"><div>Iron deposition in both hepatocytes &#x00026; Kupffer cells</div></li><li class="half_rhythm"><div>Serum hepcidin levels normal or slightly &#x02191;</div></li></ul>
</td></tr><tr><td headers="hd_h_hemochromatosis.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">African iron overload<br />(OMIM <a href="http://omim.org/entry/601195" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601195</a>)</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">?</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">?</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Iron accumulation in Kupffer cells &#x00026; hepatocytes</div></li><li class="half_rhythm"><div>Cirrhosis common</div></li></ul>
</td><td headers="hd_h_hemochromatosis.Tc_1_1_1_4 hd_h_hemochromatosis.Tc_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Affects persons of native sub-Saharan African descent</div></li><li class="half_rhythm"><div>Associated w/excessive intake of dietary iron in traditional beer brewed in non-galvanized steel drums</div></li><li class="half_rhythm"><div>Associated w/tuberculosis, hepatocellular carcinoma, &#x00026; esophageal carcinoma</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">? = unknown; AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; RE = reticuloendothelial cells; TS = transferrin saturation</p></div></dd></dl></div></div></div><div id="hemochromatosis.Secondary_Iron_Overload"><h3>Secondary Iron Overload Disorders</h3><p>Liver diseases include alcoholic liver disease, acute viral hepatitis, or chronic viral hepatitis C (uncommon), neoplasms, <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a>, and inflammatory disorders such as rheumatoid arthritis.</p><p>A very common liver condition, nonalcoholic fatty liver disease (NAFLD) (OMIM <a href="http://omim.org/entry/613282" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613282</a>), frequently causes elevated serum ferritin levels and is sometimes associated with increased hepatic iron deposition.</p><p>Iron overload can result from ingested iron in foods, cooking ware, and medicines, in addition to parenteral iron from iron injections or transfusions for chronic anemia (e.g., <a href="/books/n/gene/b-thal/">beta-thalassemia</a>, <a href="/books/n/gene/sickle/">sickle cell disease</a>, hereditary sideroblastic anemia, pyruvate kinase deficiency, <a href="/books/n/gene/epb42-spherocytosis/">hereditary spherocytosis</a>, myelodysplastic syndrome with refractory anemia).</p><p>Iron absorption is increased in some subtypes of heritable anemia, especially severe beta-thalassemia and hereditary sideroblastic anemia.</p><p>Neonatal hemochromatosis is a severe liver disease that develops in utero and is associated with extrahepatic siderosis. Gestational alloimmune liver disease is the cause of fetal liver injury resulting in nearly all cases [<a class="bk_pop" href="#hemochromatosis.REF.feldman.2013.313">Feldman &#x00026; Whitington 2013</a>]. Maternal alloimmunity accounts for the occurrence of neonatal hemochromatosis in two or more offspring of the same mother. Antenatal therapy with high-dose intravenous IgG initiated at either 18 or 14 gestational weeks prevents poor outcome of pregnancies at risk for neonatal hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.whitington.2018.218">Whitington et al 2018</a>]. There is little evidence that neonatal hemochromatosis is a heritable disorder attributed to an as-yet-unidentified <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Some investigators have suggested that pathogenic variants in <i>DGUOK</i> lead to phenotypes that resemble that of neonatal hemochromatosis (see <a href="/books/n/gene/dguok-mtddepl/">Deoxyguanosine Kinase Deficiency</a>).</p><p>See <a href="http://omim.org/phenotypicSeries/PS235200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemochromatosis: OMIM Phenotypic Series</a>, to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></div><div id="hemochromatosis.Management"><h2 id="_hemochromatosis_Management_">Management</h2><p>The European Association for the Study of the Liver (EASL) published clinical practice guidelines on the management of hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>]. The American Association for the Study of Liver Disease (AASLD) published practice guidelines for diagnosis and management of hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>] (<a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). Experts at the 2017 Hemochromatosis International meeting published an objective and practical set of recommendations on treatment of persons with hemochromatosis and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygosity based on published scientific studies and guidelines in a form suitable for patients and other persons without medical training [<a class="bk_pop" href="#hemochromatosis.REF.adams.2018.83">Adams et al 2018</a>].</p><div id="hemochromatosis.Evaluations_Following_In"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of iron overload and optimal management of persons diagnosed with <i>HFE</i> hemochromatosis, the evaluations summarized in this section (if not performed as part of the evaluation at diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Serum ferritin concentration to establish iron overload status and prognosis (see <a class="figpopup" href="/books/NBK1440/figure/hemochromatosis.F2/?report=objectonly" target="object" rid-figpopup="fighemochromatosisF2" rid-ob="figobhemochromatosisF2">Figure 2</a>)</div></li><li class="half_rhythm"><div>For <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes:</div><ul><li class="half_rhythm"><div>Liver biopsy remains the "gold standard" for establishing or excluding cirrhosis.</div></li><li class="half_rhythm"><div>Liver biopsy to evaluate for advanced hepatic fibrosis is recommended for individuals with serum ferritin &#x0003e;1,000 ng/mL or elevated serum AST and ALT levels [<a class="bk_pop" href="#hemochromatosis.REF.morrison.2003.627">Morrison et al 2003</a>, <a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>].</div></li><li class="half_rhythm"><div>Liver biopsy is not recommended for those with serum ferritin concentration &#x0003c;1,000 ng/mL and normal serum ALT and AST levels because their risk for advanced hepatic fibrosis is low [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>, <a class="bk_pop" href="#hemochromatosis.REF.barton.2018.871">Barton et al 2018</a>].</div></li></ul></li><li class="half_rhythm"><div>MRI to estimate parenchymal iron content by utilizing the paramagnetic properties of iron:</div><ul><li class="half_rhythm"><div>A specialized MRI technique with excellent <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> for estimation of hepatic iron concentration has been approved by the FDA for clinical use [<a class="bk_pop" href="#hemochromatosis.REF.st_pierre.2005.855">St Pierre et al 2005</a>]. This method of quantitative MRI (R<sub>2</sub>) accurately measures liver iron concentration (LIC) within a sufficiently wide concentration range. Compared with liver biopsy, R<sub>2</sub>-LIC is noninvasive and significantly reduces biopsy sampling error [<a class="bk_pop" href="#hemochromatosis.REF.fischer.2009.215">Fischer &#x00026; Harmatz 2009</a>]. In addition, T<sub>2</sub>*-weighted MRI measurement of liver iron is now widely available [<a class="bk_pop" href="#hemochromatosis.REF.brittenham.2003.15">Brittenham et al 2003</a>, <a class="bk_pop" href="#hemochromatosis.REF.cheong.2005.448">Cheong et al 2005</a>, <a class="bk_pop" href="#hemochromatosis.REF.ptaszek.2005.689">Ptaszek et al 2005</a>].</div></li><li class="half_rhythm"><div>Cardiac iron concentration can be monitored using similar techniques and may be of prognostic value [<a class="bk_pop" href="#hemochromatosis.REF.fischer.2009.215">Fischer &#x00026; Harmatz 2009</a>, <a class="bk_pop" href="#hemochromatosis.REF.ramazzotti.2009.62">Ramazzotti et al 2009</a>].</div></li></ul></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighemochromatosisF2" co-legend-rid="figlgndhemochromatosisF2"><a href="/books/NBK1440/figure/hemochromatosis.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="fighemochromatosisF2" rid-ob="figobhemochromatosisF2"><img class="small-thumb" src="/books/NBK1440/bin/hemochromatosis-Image002.gif" src-large="/books/NBK1440/bin/hemochromatosis-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndhemochromatosisF2"><h4 id="hemochromatosis.F2"><a href="/books/NBK1440/figure/hemochromatosis.F2/?report=objectonly" target="object" rid-ob="figobhemochromatosisF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Use of serum ferritin concentration to direct management </p></div></div><div id="hemochromatosis.Clinical_HFE_Hemochromat_1"><h4>Clinical <i>HFE</i> Hemochromatosis</h4><p><b>Therapeutic phlebotomy</b> is indicated in the presence of symptoms of iron overload or evidence of end-organ damage (e.g., cirrhosis, cardiac failure, skin hyperpigmentation, diabetes, or hypogonadotrophic hypogonadism):</p><ul><li class="half_rhythm"><div class="half_rhythm">Periodic phlebotomy is a simple, inexpensive, safe, and effective treatment.</div><ul><li class="half_rhythm"><div>Each unit of blood (500 mL) with a hematocrit of 40% removes 200 mg of iron.</div></li><li class="half_rhythm"><div>Each mL of packed red blood cells contains 1 mg of iron.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">The usual therapy is weekly phlebotomy (i.e., removal of a unit of blood) until the serum ferritin concentration is &#x02264;50 ng/mL. Twice-weekly phlebotomy is useful to accelerate iron depletion in some patients. Some persons, especially women, tolerate phlebotomy therapy less frequently (every 10-14 days) or at lower volume per phlebotomy.</div></li><li class="half_rhythm"><div class="half_rhythm">Phlebotomy is performed at intervals until the hematocrit is 75% of the baseline hematocrit.</div></li><li class="half_rhythm"><div class="half_rhythm">The serum ferritin concentration is the most reliable and inexpensive way to monitor therapeutic phlebotomy. If the serum ferritin concentration is &#x02265;50 ng/mL despite a significant reduction in hematocrit, the frequency at which phlebotomy is performed needs to be increased. After the serum ferritin concentration is &#x02264;100 ng/mL, serum ferritin concentration should be quantified after each additional one or two treatments [<a class="bk_pop" href="#hemochromatosis.REF.barton.1998.932">Barton et al 1998</a>]. On average, men require removal of twice as many units of blood to achieve iron depletion as women.</div></li><li class="half_rhythm"><div class="half_rhythm">Maintenance phlebotomy to prevent reaccumulation of excess iron is indicated for men whose serum ferritin levels exceed 300 ng/mL and for women whose serum ferritin levels exceed 200 ng/mL [<a class="bk_pop" href="#hemochromatosis.REF.adams.2010.317">Adams &#x00026; Barton 2010</a>].</div><div class="half_rhythm">Whether lowering TS should be a target of phlebotomy therapy is debatable. Elevated TS in <i>HFE</i> hemochromatosis is caused by increased iron export from macrophages due to hepcidin deficiency and is not a marker of iron overload. Attempting to achieve and maintain low TS in <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes may result in iron deficiency and associated manifestations [<a class="bk_pop" href="#hemochromatosis.REF.barton.2000.223">Barton &#x00026; Bottomley 2000</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Individuals with <i>HFE</i> hemochromatosis rarely need iron chelation therapy. Iron chelation therapy is not recommended unless an individual has an elevated serum ferritin concentration and concomitant anemia, inadequate venous access, or another circumstance that makes therapeutic phlebotomy impossible.</div><div class="half_rhythm">Therapeutic phlebotomy significantly decreases hepatic fibrosis in many persons with <i>HFE</i> p.Cys282Tyr homozygosity, including more than one third of those with cirrhosis. A combination of simple biochemical tests performed before phlebotomy therapy can predict those in whom fibrosis or cirrhosis is reversible [<a class="bk_pop" href="#hemochromatosis.REF.falize.2006.472">Falize et al 2006</a>].</div></li></ul><p><b>Orthotopic liver transplantation</b> is the treatment for end-stage liver disease due to decompensated cirrhosis. The post-transplant survival among individuals with <i>HFE</i> hemochromatosis is poor [<a class="bk_pop" href="#hemochromatosis.REF.crawford.2004.1655">Crawford et al 2004</a>, <a class="bk_pop" href="#hemochromatosis.REF.kowdley.2005.494">Kowdley et al 2005</a>]. In a study of 18 <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes, post-transplant survival was similar to that of individuals with other causes of end-stage liver disease [<a class="bk_pop" href="#hemochromatosis.REF.bardoujacquet.2014.839">Bardou-Jacquet et al 2014</a>].</p></div><div id="hemochromatosis.Biochemical_HFE_Hemochro_1"><h4>Biochemical <i>HFE</i> Hemochromatosis</h4><p>Both the EASL and AASLD guidelines recommend therapeutic phlebotomy for persons with biochemical <i>HFE</i> hemochromatosis (i.e., those who have increased body iron stores in the absence of clinical evidence of iron overload). See <a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver [2010]</a> and <a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al [2011]</a> (<a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). The exact serum ferritin concentration at which therapeutic phlebotomy should be initiated is not clear. The European Association for the Study of the Liver suggests performing phlebotomy when the serum ferritin concentration exceeds 500 ng/mL. In a study of Australian <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> homozygotes, there was evidence of subjective and objective improvement by reducing serum ferritin levels to &#x0003c;300 ng/mL [<a class="bk_pop" href="#hemochromatosis.REF.ong.2017.e607">Ong et al 2017</a>].</p></div><div id="hemochromatosis.NonExpressing_p_Cys282Ty_1"><h4>Non-Expressing p.Cys282Tyr Homozygotes</h4><p>These individuals do not have iron overload and thus do not need phlebotomy.</p></div></div><div id="hemochromatosis.Prevention_of_Secondary"><h3>Prevention of Secondary Complications</h3><p>Vaccination against hepatitis A and B is advised [<a class="bk_pop" href="#hemochromatosis.REF.tavill.2001.1321">Tavill 2001</a>].</p></div><div id="hemochromatosis.Surveillance"><h3>Surveillance</h3><div id="hemochromatosis.Primary_Liver_Cancer"><h4>Primary Liver Cancer</h4><p>Individuals who have hemochromatosis and cirrhosis may develop primary liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or a combination of these histologic types. The American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) published guidelines on surveillance for primary liver cancer among patients who have both cirrhosis and hemochromatosis.</p><p>The AASLD advised surveillance using hepatic ultrasonography every six months [<a class="bk_pop" href="#hemochromatosis.REF.bruix.2005.1208">Bruix et al 2005</a>, <a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>, <a class="bk_pop" href="#hemochromatosis.REF.bruix.2011.1020">Bruix et al 2011</a>]. The EASL advised both hepatic ultrasonography and measurement of serum alphafetoprotein every six months [<a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>].</p><p>Authors of a recent study discussed the similarities, differences, and overall quality of hemochromatosis practice guidelines, not confined to surveillance. The conclusions were that the guidelines differed in many ways and that the overall quality of the AASLD, EASL, and Dutch practice guidelines was not high [<a class="bk_pop" href="#hemochromatosis.REF.swinkels.2007.452">Swinkels et al 2007</a>, <a class="bk_pop" href="#hemochromatosis.REF.vanclooster.2015.205">Vanclooster et al 2015</a>]. An AASLD publication [<a class="bk_pop" href="#hemochromatosis.REF.bruix.2011.1020">Bruix et al 2011</a>] stated that their surveillance algorithm [<a class="bk_pop" href="#hemochromatosis.REF.bruix.2005.1208">Bruix et al 2005</a>] for hepatocellular carcinoma had been validated.</p></div><div id="hemochromatosis.Clinical_HFE_Hemochromat_2"><h4>Clinical <i>HFE</i> Hemochromatosis</h4><p>Once the serum ferritin concentration is &#x0003c;50 ng/mL, monitor serum ferritin every three to four months.</p><p>It is reasonable to perform follow-up T<sub>2</sub>*-weighted MRI for assessment of cardiac iron among persons with a history of cardiac involvement or known cardiac iron deposition.</p><p>Cirrhosis is a crucial stage in the natural history of hemochromatosis; thus, the diagnosis of cirrhosis is important because management and clinical outcomes change. Individuals with cirrhosis should be evaluated regularly and screened for primary liver cancer. The AASLD practice guidelines recommend imaging every six months with ultrasonography [<a class="bk_pop" href="#hemochromatosis.REF.bruix.2011.1020">Bruix et al 2011</a>]. This may be accompanied with measurement of alpha fetoprotein. Noninvasive methods that use results derived from values of serum markers such as HepaScore<sup>&#x000ae;</sup> and FibroMeter&#x02122; can also be used to assess the stage of liver fibrosis [<a class="bk_pop" href="#hemochromatosis.REF.mart_nez.2011.325">Mart&#x000ed;nez et al 2011</a>].</p><p>Although the "gold standard" for the diagnosis of cirrhosis is biopsy, FibroScan<sup>&#x000ae;</sup> has good <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity for cirrhosis [<a class="bk_pop" href="#hemochromatosis.REF.tsochatzis.2011.650">Tsochatzis et al 2011</a>]. FibroScan transient elastography (TE) quantifies fibrosis with ultrasound in a noninvasive manner [<a class="bk_pop" href="#hemochromatosis.REF.tsochatzis.2011.650">Tsochatzis et al 2011</a>]. The results from a meta-analysis suggested a cutoff value for diagnosis of cirrhosis of 13.01 kPa [<a class="bk_pop" href="#hemochromatosis.REF.friedrichrust.2008.960">Friedrich-Rust et al 2008</a>]. Individuals with normal TE values on FibroScan would not need a biopsy. Individuals with intermediate or high TE values should have biopsies to confirm cirrhosis. These results should be interpreted in conjunction with clinical and biochemical parameters.</p><p>The AASLD guidelines recommend that individuals with cirrhosis undergo surveillance for primary liver cancer whether they have achieved iron depletion or not [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>] (<a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p></div><div id="hemochromatosis.Biochemical_HFE_Hemochro_2"><h4>Biochemical <i>HFE</i> Hemochromatosis</h4><p>Begin annual measurement of serum ferritin concentration when values exceed normal levels [<a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>].</p></div><div id="hemochromatosis.NonExpressing_p_Cys282Ty_2"><h4>Non-Expressing p.Cys282Tyr Homozygotes</h4><p>Begin annual measurement of serum ferritin concentration when values exceed normal levels [<a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>].</p></div></div><div id="hemochromatosis.AgentsCircumstances_to_A"><h3>Agents/Circumstances to Avoid</h3><p>Medicinal iron, mineral supplements, excess vitamin C, uncooked seafood, alcohol consumption in individuals with cirrhosis or other liver disease, and daily ingestion of more than 500 mg of supplemental ascorbic acid / vitamin C should be avoided.</p></div><div id="hemochromatosis.Evaluation_of_Relatives"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the status of adult sibs and offspring of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> in order to identify those who would benefit from prompt initiation of treatment and preventive measures.</p><p>The following strategy is appropriate:</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to the adult sibs (&#x02265;18 years) of an individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr.</p></dd><dt>2.</dt><dd><p class="no_top_margin">Measure TS and serum ferritin level of sibs who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr.</p></dd><dt>3.</dt><dd><p class="no_top_margin">Begin phlebotomy therapy if serum ferritin concentration is elevated and if the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has clinical <i>HFE</i> hemochromatosis. Sibs of probands with clinical <i>HFE</i> hemochromatosis have a higher prevalence of clinical <i>HFE</i> hemochromatosis than asymptomatic individuals with <i>HFE</i> hemochromatosis detected through screening programs [<a class="bk_pop" href="#hemochromatosis.REF.bulaj.2000.1529">Bulaj et al 2000</a>].</p></dd></dl><p>Targeted testing for p.Cys282Tyr is cost effective in most individuals because it has excellent negative predictive value. Genotype-based testing has a low positive predictive value because many p.Cys282Tyr homozygotes and compound heterozygotes do not develop iron overload [<a class="bk_pop" href="#hemochromatosis.REF.elserag.2000.261">El-Serag et al 2000</a>, <a class="bk_pop" href="#hemochromatosis.REF.beutler.2002.211">Beutler et al 2002</a>].</p><p>See <a href="#hemochromatosis.Related_Genetic_Counseli">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hemochromatosis.Pregnancy_Management"><h3>Pregnancy Management</h3><p>No guidelines exist. It is common practice to withhold phlebotomy during pregnancy.</p></div><div id="hemochromatosis.Therapies_Under_Investig"><h3>Therapies Under Investigation</h3><p>The oral iron chelator deferasirox (Exjade<sup>&#x000ae;</sup>) has been evaluated in a Phase I/II study of individuals with hemochromatosis. Results of this trial suggest that deferasirox is effective at reducing iron burdens within an acceptable safety profile [<a class="bk_pop" href="#hemochromatosis.REF.phatak.2010.1671">Phatak et al 2010</a>]. The intravenous iron chelator deferoxamine has been studied in 24 persons with hemochromatosis [<a class="bk_pop" href="#hemochromatosis.REF.saddi.1978.41">Saddi et al 1978</a>]. Severe cardiac siderosis in a patient with juvenile hemochromatosis was treated with success using a combination of deferoxamine and deferiprone [<a class="bk_pop" href="#hemochromatosis.REF.fabio.2007.362">Fabio et al 2007</a>]. To date, the US Food and Drug Administration has not approved deferasirox, deferoxamine, or deferiprone for treatment of hemochromatosis.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="hemochromatosis.Genetic_Counseling"><h2 id="_hemochromatosis_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hemochromatosis.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>HFE</i> hemochromatosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="hemochromatosis.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most parents of individuals with <i>HFE</i> hemochromatosis are heterozygotes (i.e., carriers of one <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a pathogenic <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> do not develop iron overload, but some have abnormal serum iron studies [<a class="bk_pop" href="#hemochromatosis.REF.adams.2005.1769">Adams et al 2005</a>]. (See Clinical Description, <a href="#hemochromatosis.Heterozygotes">Heterozygotes</a>.)</div></li><li class="half_rhythm"><div>On occasion, one parent has <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HFE</i> pathogenic variants and may have clinical <i>HFE</i> hemochromatosis (presence of significant end-organ damage including cirrhosis, cardiac failure, skin hyperpigmentation, diabetes, or hypogonadism). Thus, it is appropriate to evaluate the parents of an individual with <i>HFE</i> hemochromatosis by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the pathogenic variants identifed in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> or by transferrin saturation (TS) and serum ferritin levels.</div></li><li class="half_rhythm"><div>Pseudodominance (the occurrence of an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder in two generations of a family without <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>) has been observed in <i>HFE</i> hemochromatosis and is attributed to the high <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of <i>HFE</i> pathogenic variants <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.His63Asp</a> in persons of European origin (see <a href="#hemochromatosis.Prevalence">Prevalence</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>If both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has at conception a 25% chance of inheriting both <i>HFE</i> pathogenic variants, a 50% chance of inheriting one <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and a 25% chance of inheriting neither <i>HFE</i> pathogenic variant.</div></li><li class="half_rhythm"><div>When one parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> and the other parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each sib of an individual with <i>HFE</i> hemochromatosis has a 50% chance of inheriting both <i>HFE</i> pathogenic variants and a 50% chance of inheriting one <i>HFE</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Sibs who inherit <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HFE</i> pathogenic variants may or may not exhibit clinical <i>HFE</i> hemochromatosis or biochemical <i>HFE</i> hemochromatosis (see <a href="#hemochromatosis.Penetrance">Penetrance</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Unless an individual with <i>HFE</i> hemochromatosis has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>), his/her offspring will be obligate heterozygotes for an <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The risk that a northern European reproductive partner of an individual with <i>HFE</i> hemochromatosis is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Cys282Tyr</a> is approximately 1/9. Thus, the risk to the offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> of being <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Cys282Tyr is approximately 5% (i.e., 1/9 x 1/2 = 1/18).</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="hemochromatosis.Carrier_Heterozygote_Det"><h3>Carrier (Heterozygote) Detection</h3><p>Molecular genetic <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> of at-risk relatives is most informative if the <i>HFE</i> pathogenic variants in the family have been identified.</p><p>Screening for <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status can be offered to the reproductive partner of a person with <i>HFE</i> hemochromatosis to determine if their offspring are at risk for <i>HFE</i> hemochromatosis.</p></div><div id="hemochromatosis.Related_Genetic_Counseli"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hemochromatosis.Evaluation_of_Relatives">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of persons with clinical hemochromatosis phenotypes whose <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is not diagnostic of <i>HFE</i> hemochromatosis.</p></div><div id="hemochromatosis.Population_Screening"><h3>Population Screening</h3><p>Population screening has been considered due to the high prevalence of <i>HFE</i> hemochromatosis, the lack of early clinical findings, the lack of specificity of clinical findings if they appear, the low cost of diagnosis, the relatively simple and effective early treatment, and the high cost and low success rate of treatment when the diagnosis is established late.</p><p><b>Genotype-based population screening of <i>HFE</i> hemochromatosis</b> is not recommended because <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is low and the natural history of untreated individuals cannot be predicted. See <a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver [2010]</a> and <a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al [2011]</a> (<a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p><b>Biochemical-based screening</b> (using TS and serum ferritin) of men of northern European descent who are older than age 30 years may be considered [<a class="bk_pop" href="#hemochromatosis.REF.phatak.2008.270">Phatak et al 2008</a>, <a class="bk_pop" href="#hemochromatosis.REF3">European Association for the Study of the Liver 2010</a>, <a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>].</p></div><div id="hemochromatosis.Prenatal_Testing_and_Pre"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Although prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible once the <i>HFE</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing is not usually performed because <i>HFE</i> hemochromatosis is an adult-onset, treatable disorder with low clinical <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div></div><div id="hemochromatosis.Resources"><h2 id="_hemochromatosis_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Hemochromatosis Society, Inc.</b></div><div>P.O. Box 950871</div><div>Lake Mary FL 32795-0871</div><div><b>Phone:</b> 407-829-4488; 888-655-IRON (4766)</div><div><b>Fax:</b> 407-333-1284</div><div><b>Email:</b> mail@americanhs.org</div><div><a href="http://www.americanhs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.americanhs.org</a></div></li><li class="half_rhythm"><div><b>Canadian Hemochromatosis Society</b></div><div>7000 Minoru Boulevard</div><div>Suite 285</div><div>Richmond British Columbia V6Y 3Z5</div><div>Canada</div><div><b>Phone:</b> 877-BAD-IRON (1-877-223-4766); 604-279-7135</div><div><b>Email:</b> office@toomuchiron.ca</div><div><a href="https://www.toomuchiron.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.toomuchiron.ca</a></div></li><li class="half_rhythm"><div><b>EFAPH: European Federation of Associations of Patients with Haemochromatosis</b></div><div>4 rue Paul Demange</div><div>Croissy-sur-Seine F-78290</div><div>France</div><div><b>Phone:</b> 00 33 (0)6 08 25 94 04</div><div><b>Email:</b> fcourtois.dom@wanadoo.fr; efaph@gmx.eu</div><div><a href="http://efaph.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.efaph.eu</a></div></li><li class="half_rhythm"><div><b>Haemochromatosis Australia</b></div><div>Australia</div><div><b>Phone:</b> 1300 019 028</div><div><a href="http://haemochromatosis.org.au/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.haemochromatosis.org.au</a></div></li><li class="half_rhythm"><div><b>Haemochromatosis Society</b></div><div>Haemochromatosis UK Office</div><div>Henrith Business Centre, 3 Enterprise Way</div><div>Pinchbeck, Spalding Lincolnshire PE11 3YR</div><div>United Kingdom</div><div><b>Phone:</b> 03030 401 101; 03030 401 102</div><div><b>Email:</b> office@huk.org.uk; helpline@huk.org.uk</div><div><a href="http://haemochromatosis.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.haemochromatosis.org.uk</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=HFE-associated%20Hereditary%20Hemochromatosis&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HFE-Associated Hereditary Hemochromatosis</a></div></li><li class="half_rhythm"><div><b>National Digestive Diseases Information Clearinghouse (NDDIC)</b></div><div>2 Information Way</div><div>Bethesda MD 20892-3570</div><div><b>Phone:</b> 800-891-5389 (toll-free); 866-569-1162 (TTY)</div><div><b>Fax:</b> 703-738-4929</div><div><b>Email:</b> nddic@info.niddk.nih.gov</div><div><a href="https://www.niddk.nih.gov/health-information/liver-disease/hemochromatosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemochromatosis</a></div></li><li class="half_rhythm"><div><b>National Human Genome Research Institute (NHGRI)</b></div><div><a href="http://www.genome.gov/10001214" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Learning About Hereditary Hemochromatosis</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/hereditary-hemochromatosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22223/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis</a></div></li></ul></div><div id="hemochromatosis.Molecular_Genetics"><h2 id="_hemochromatosis_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hemochromatosis.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>HFE Hemochromatosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1440/table/hemochromatosis.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hemochromatosis.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hemochromatosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3077" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HFE</i></a></td><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3077" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p22<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q30201" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis protein</a></td><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://alsod.iop.kcl.ac.uk/Als/Overview/gene.aspx?gene_id=HFE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alsod/HFE genetic mutations</a><br /><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=1&#x00026;geneId=EG3077" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALS mutation database (HFE)</a><br /><a href="http://databases.lovd.nl/shared/genes/HFE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HFE database</a></td><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HFE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HFE</a></td><td headers="hd_b_hemochromatosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HFE[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HFE</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hemochromatosis.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hemochromatosis.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for HFE Hemochromatosis (<a href="/omim/235200,613609" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1440/table/hemochromatosis.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hemochromatosis.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/235200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">235200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOCHROMATOSIS, TYPE 1; HFE1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613609" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613609</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HFE GENE; HFE</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The size of <i>HFE</i> is approximately 13 kb. <i>HFE</i> has seven exons. <i>HFE</i> gives rise to at least 11 alternative transcripts encoding four to seven exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1440/#hemochromatosis.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic <i>HFE</i> alleles.</b> Most persons with <i>HFE</i> hemochromatosis phenotypes have: (1) homozygosity for p.Cys282Tyr; (2) compound heterozygosity for p.Cys282Tyr and p.His63Asp; or (3) compound heterozygosity for p.Cys282Tyr and a novel or other population-specific deleterious <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>].</p><ul><li class="half_rhythm"><div>p.Cys282Tyr removes a highly conserved cysteine residue that normally forms an intermolecular disulfide bond with beta-2-microglobulin and thereby prevents extracellular presentation of HFE protein.</div></li><li class="half_rhythm"><div>p.His63Asp may alter a pH-dependent intramolecular salt bridge, possibly affecting interaction of HFE protein with the transferrin receptor.</div></li></ul><p>The variant p.Ser65Cys occurs in combination with p.Cys282Tyr in some individuals with iron overload [<a class="bk_pop" href="#hemochromatosis.REF.bacon.2011">Bacon et al 2011</a>]. Unlike individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the common pathogenic variants, no p.Ser65Cys/wild type heterozygotes had elevation of both serum TS and ferritin.</p><p>Nearly 100 <i>HFE</i> pathogenic variants have been reported. Most are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants. Many have been described from single families or from small isolated populations. Many persons with unusual <i>HFE</i> hemochromatosis-associated genotypes are compound heterozygotes for p.Cys282Tyr and a novel <i>HFE</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>, <a class="bk_pop" href="#hemochromatosis.REF.edwards.2018">Edwards &#x00026; Barton 2018</a>].</p><p>Population-specific pathogenic variants have been described, including <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Glu168Ter</a> and <a class="figpopup" href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="fighemochromatosisThfepathogenicvariant" rid-ob="figobhemochromatosisThfepathogenicvariant">p.Trp169Ter</a>, found with an <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> respectively of 25% and 8.4% in individuals with hemochromatosis in two northern regions of Italy [<a class="bk_pop" href="#hemochromatosis.REF.piperno.2000.441">Piperno et al 2000</a>]. The prevalence of <i>HFE</i> p.Ser65Cys is greatest in French populations. The <i>HFE</i> <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant c.1006+1G&#x0003e;A occurs in Vietnamese with and without phenotypic evidence of iron overload [<a class="bk_pop" href="#hemochromatosis.REF.barton.2015.179">Barton et al 2015</a>]. Deletion of <i>HFE</i> is the most common cause of hemochromatosis in the Sardinian population [<a class="bk_pop" href="#hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</a>].</p><div id="hemochromatosis.T.hfe_pathogenic_variant" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>HFE</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1440/table/hemochromatosis.T.hfe_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hemochromatosis.T.hfe_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.187C&#x0003e;G</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His63Asp</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000410.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000410<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000401.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000401<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.193A&#x0003e;T</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser65Cys</td></tr><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.502G&#x0003e;T</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu168Ter</td></tr><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.506G&#x0003e;A</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp169Ter</td></tr><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.845G&#x0003e;A</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys282Tyr</td></tr><tr><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1006+1G&#x0003e;A</td><td headers="hd_h_hemochromatosis.T.hfe_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The largest predicted primary translation product is 348 amino acids, which gives rise to a mature protein of approximately 321 amino acids after cleavage of the signal sequence. The HFE protein is similar to HLA Class I molecules at the level of their primary structure [<a class="bk_pop" href="#hemochromatosis.REF.feder.1996.399">Feder et al 1996</a>] and tertiary structure [<a class="bk_pop" href="#hemochromatosis.REF.lebr_n.1998.111">Lebr&#x000f3;n et al 1998</a>]. The mature protein is expressed on the cell surface as a heterodimer with beta-2-microglobulin, and this interaction is necessary for normal presentation on the cell surface. Normal HFE protein binds to transferrin receptor 1 on the cell surface. The means by which the HFE protein regulates iron uptake is unclear [<a class="bk_pop" href="#hemochromatosis.REF.fleming.2004.755">Fleming et al 2004</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Hemochromatosis occurs through a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism. The p.Cys282Tyr variant results in an HFE protein that lacks a key cysteine residue that is required for disulfide bonding with beta-2-microglobulin. As a result, p.Cys282Tyr-containing protein becomes trapped in the endoplasmic reticulum and Golgi apparatus, leading to decreased cell-surface expression.</p><p>The p.His63Asp variant results in an abnormal HFE protein that is predicted to disrupt a salt bridge in the HFE &#x003b1;2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that binds the transferrin receptor, indicating that the salt bridge and binding of the transferrin receptor to its ligand are important for normal HFE function. The p.His63Asp variant does not affect HFE cell-surface presentation.</p><p>The p.Ser65Cys variant alters the HFE &#x003b1;1 binding groove for the transferrin receptor. Because the p.Ser65Cys is two amino acids distal to that of p.His63Asp, p.Ser65Cys may alter transferrin / transferrin-receptor binding by a mechanism similar to p.His63Asp. The variant p.Ser65Cys does not affect HFE cell surface presentation.</p><p>The mechanistic basis for the phenotypic effects of other <i>HFE</i> pathogenic variants is not clear.</p></div><div id="hemochromatosis.References"><h2 id="_hemochromatosis_References_">References</h2><div id="hemochromatosis.Published_Guidelines__Co"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bacon.2011">Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Available <a href="/pmc/articles/PMC3149125/?tool=pubmed" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 11-26-18. [<a href="/pmc/articles/PMC3149125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3149125</span></a>] [<a href="/pubmed/21452290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21452290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF2">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 11-26-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF3">European Association for the Study of the Liver. EASL clinical practice guidelines for <em>HFE</em> hemochromatosis. 2010. [<a href="/pubmed/20471131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20471131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF4">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 11-26-18.</div></li></ul></div><div id="hemochromatosis.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.adams.2018.83">Adams P, Altes A, Brissot P, Butzeck B, Cabantchik I, Can&#x000e7;ado R, Distante S, Evans P, Evans R, Ganz T, Girelli D, Hultcrantz R, McLaren G, Marris B, Milman N, Nemeth E, Nielsen P, Pineau B, Piperno A, Porto G, Prince D, Ryan J, Sanchez M, Santos P, Swinkels D, Teixeira E, Toska K, Vanclooster A, White D, et al.  Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. <span><span class="ref-journal">Hepatol Int. </span>2018;<span class="ref-vol">12</span>:83–6.</span> [<a href="/pmc/articles/PMC5904234/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5904234</span></a>] [<a href="/pubmed/29589198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29589198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.adams.2010.317">Adams PC, Barton JC. How I treat hemochromatosis. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:317–25.</span> [<a href="/pubmed/20308595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20308595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.adams.2005.1769">Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:1769–78.</span> [<a href="/pubmed/15858186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15858186</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.allen.2010.925">Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, McLaren CE, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC, et al.  <em>HFE</em> Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:925–33.</span> [<a href="/pmc/articles/PMC2932765/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2932765</span></a>] [<a href="/pubmed/20583211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20583211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.allen.2008.221">Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in <em>HFE</em> hereditary hemochromatosis. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:221–30.</span> [<a href="/pubmed/18199861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18199861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bacon.2011.328">Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, et al.  Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">54</span>:328–43.</span> [<a href="/pmc/articles/PMC3149125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3149125</span></a>] [<a href="/pubmed/21452290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21452290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bardoujacquet.2015a.1917">Bardou-Jacquet E, de Tayrac M, Mosser J, Deugnier Y. <em>GNPAT</em> variant associated with severe iron overload in <em>HFE</em> hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2015a;<span class="ref-vol">62</span>:1917–8.</span> [<a href="/pubmed/25891252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25891252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bardoujacquet.2015b.283">Bardou-Jacquet E, Lain&#x000e9; F, Deugnier Y. Reply to: "Reduced mortality due to phlebotomy in moderately iron-loaded <em>HFE</em> haemochromatosis? The need for clinical trials. <span><span class="ref-journal">J Hepatol. </span>2015b;<span class="ref-vol">63</span>:283–4.</span> [<a href="/pubmed/25841362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25841362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bardoujacquet.2015c.682">Bardou-Jacquet E, Morcet J, Manet G, Lain&#x000e9; F, Perrin M, Jouanolle AM, Guyader D, Moirand R, Viel JF, Deugnier Y. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild <em>HFE</em> hemochromatosis. <span><span class="ref-journal">J Hepatol. </span>2015c;<span class="ref-vol">62</span>:682–9.</span> [<a href="/pubmed/25450707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25450707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bardoujacquet.2014.839">Bardou-Jacquet E, Philip J, Lorho R, Ropert M, Latournerie M, Houssel-Debry P, Guyader D, Lor&#x000e9;al O, Boudjema K, Brissot P. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2014;<span class="ref-vol">59</span>:839–47.</span> [<a href="/pubmed/23775519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23775519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.barton.2000.223">Barton JC, Bottomley SS. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. <span><span class="ref-journal">Am J Hematol. </span>2000;<span class="ref-vol">65</span>:223–6.</span> [<a href="/pubmed/11074539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11074539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.barton.2017.15">Barton JC, Chen WP, Emond MJ, Phatak PD, Subramaniam VN, Adams PC, Gurrin LC, Anderson GJ, Ramm GA, Powell LW, Allen KJ, Phillips JD, Parker CJ, McLaren GD, McLaren CE. GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2017;<span class="ref-vol">63</span>:15–20.</span> [<a href="/pmc/articles/PMC5629344/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5629344</span></a>] [<a href="/pubmed/27936396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27936396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.barton.2015.179">Barton JC, Edwards CQ, Acton RT. HFE gene: structure, function, mutations, and associated iron abnormalities. <span><span class="ref-journal">Gene. </span>2015;<span class="ref-vol">574</span>:179–92.</span> [<a href="/pmc/articles/PMC6660136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6660136</span></a>] [<a href="/pubmed/26456104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26456104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.barton.1998.932">Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ, Cook JD, Kowdley KV. Management of hemochromatosis. Hemochromatosis Management Working Group. <span><span class="ref-journal">Ann Intern Med. </span>1998;<span class="ref-vol">129</span>:932–9.</span> [<a href="/pubmed/9867745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9867745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.barton.2018.871">Barton JC, McLaren CE, Chen WP, Ramm GA, Anderson GJ, Powell LW, Subramaniam VN, Adams PC, Phatak PD, Gurrin LC, Phillips JD, Parker CJ, Emond MJ, McLaren GD. Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p.C282Y homozygotes. <span><span class="ref-journal">Ann Hepatol. </span>2018;<span class="ref-vol">17</span>:871–9.</span> [<a href="/pmc/articles/PMC6368858/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6368858</span></a>] [<a href="/pubmed/30145563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30145563</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.beutler.2002.211">Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G--&#x0003e;A (C282Y) <em>HFE</em> hereditary haemochromatosis mutation in the USA. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>:211–8.</span> [<a href="/pubmed/11812557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11812557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.brittenham.2003.15">Brittenham GM, Badman DG, et al.  Noninvasive measurement of iron: report of an NIDDK workshop. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:15–9.</span> [<a href="/pubmed/12393526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12393526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bruix.2005.1208">Bruix J, Sherman M, et al.  Management of hepatocellular carcinoma. <span><span class="ref-journal">Hepatology. </span>2005;<span class="ref-vol">42</span>:1208–36.</span> [<a href="/pubmed/16250051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16250051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bruix.2011.1020">Bruix J, Sherman M, et al.  Management of hepatocellular carcinoma: an update. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>:1020–2.</span> [<a href="/pmc/articles/PMC3084991/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3084991</span></a>] [<a href="/pubmed/21374666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21374666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bulaj.2000.1529">Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP. Disease-related conditions in relatives of patients with hemochromatosis. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">343</span>:1529–35.</span> [<a href="/pubmed/11087882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11087882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.bulaj.1996.1799">Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">335</span>:1799–805.</span> [<a href="/pubmed/8943161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8943161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.cheong.2005.448">Cheong B, Huber S, Muthupillai R, Flamm SD. Evaluation of myocardial ironoverload by T2* cardiovascular magnetic resonance imaging. <span><span class="ref-journal">Tex Heart Inst J. </span>2005;<span class="ref-vol">32</span>:448–9.</span> [<a href="/pmc/articles/PMC1336733/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1336733</span></a>] [<a href="/pubmed/16392242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16392242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.crawford.2004.1655">Crawford DH, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, Jeffrey GP, McCaughan GW, Kerlin P, Powell LW, Elias EE. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. <span><span class="ref-journal">Hepatology. </span>2004;<span class="ref-vol">39</span>:1655–62.</span> [<a href="/pubmed/15185307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15185307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.delatycki.2015.282">Delatycki MB, Gurrin LC, Ong SY, Ramm GA, Anderson GJ, Olynyk JK, Allen KJ, Nicoll AJ, Powell LW. Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials. <span><span class="ref-journal">J Hepatol. </span>2015;<span class="ref-vol">63</span>:282–3.</span> [<a href="/pubmed/25839407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25839407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.edwards.2018">Edwards CQ, Barton JC. Hemochromatosis. In: Greer JP, Appelbaum F, Arber DA, Dispenzieri A, Fehniger T, Glader B, List AF, Means RT, Rodgers GM, eds. <em>Wintrobe&#x02019;s Clinical Hematology</em>. 14 ed. Philadelphia, PA: Wolters-Kluwer/Lippincott Williams and Wilkins; 2018:ch 27.</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.eijkelkamp.2000.121">Eijkelkamp EJ, Yapp TR, Powell LW. HFE-associated hereditary hemochromatosis. <span><span class="ref-journal">Can J Gastroenterol. </span>2000;<span class="ref-vol">14</span>:121.</span> [<a href="/pubmed/10694284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10694284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.elserag.2000.261">El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. <span><span class="ref-journal">Ann Intern Med. </span>2000;<span class="ref-vol">132</span>:261–9.</span> [<a href="/pubmed/10681280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10681280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.european_association_for_the_study_of_the_liver.2010.3">European Association for the Study of the Liver.  EASL clinical practice guidelines for HFE hemochromatosis. <span><span class="ref-journal">J Hepatol. </span>2010;<span class="ref-vol">53</span>:3–22.</span> [<a href="/pubmed/20471131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20471131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.fabio.2007.362">Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:362–4.</span> [<a href="/pubmed/16960153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16960153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.falize.2006.472">Falize L, Guillygomarc'h A, Perrin M, Lain&#x000e9; F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. <span><span class="ref-journal">Hepatology. </span>2006;<span class="ref-vol">44</span>:472–7.</span> [<a href="/pubmed/16871557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16871557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.feder.1996.399">Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">13</span>:399–408.</span> [<a href="/pubmed/8696333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8696333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.feldman.2013.313">Feldman AG, Whitington PF. Neonatal hemochromatosis. <span><span class="ref-journal">J Clin Exp Hepatol. </span>2013;<span class="ref-vol">3</span>:313–20.</span> [<a href="/pmc/articles/PMC3940210/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3940210</span></a>] [<a href="/pubmed/25755519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25755519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.fischer.2009.215">Fischer R, Harmatz P. Non-invasive assessment of tissue iron overload. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2009:215–21.</span> [<a href="/pubmed/20008201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20008201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.fleming.2004.755">Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis. <span><span class="ref-journal">Clin Liver Dis. </span>2004;<span class="ref-vol">8</span>:755–73.</span> [<a href="/pubmed/15464654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15464654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.fletcher.2002.281">Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. <span><span class="ref-journal">Gastroenterology. </span>2002;<span class="ref-vol">122</span>:281–9.</span> [<a href="/pubmed/11832443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11832443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.friedrichrust.2008.960">Friedrich-Rust M, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">134</span>:960–74.</span> [<a href="/pubmed/18395077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18395077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.gan.2011.293">Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. <span><span class="ref-journal">Semin Liver Dis. </span>2011;<span class="ref-vol">31</span>:293–301.</span> [<a href="/pubmed/21901659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21901659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.gochee.2002.646">Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. <span><span class="ref-journal">Gastroenterology. </span>2002;<span class="ref-vol">122</span>:646–51.</span> [<a href="/pubmed/11874997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11874997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.gurrin.2009.94">Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Nicoll AJ, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ, et al.  HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-relatedmorbidity. <span><span class="ref-journal">Hepatology. </span>2009;<span class="ref-vol">50</span>:94–101.</span> [<a href="/pmc/articles/PMC3763940/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3763940</span></a>] [<a href="/pubmed/19554541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19554541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.gurrin.2008.1945">Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ, et al.  The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1945–52.</span> [<a href="/pubmed/18848943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18848943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.kowdley.2005.494">Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe EB, Gordon F, Polissar N. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. <span><span class="ref-journal">Gastroenterology. </span>2005;<span class="ref-vol">129</span>:494–503.</span> [<a href="/pubmed/16083706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16083706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.le_gac.2010.685">Le Gac G, Congiu R, Gourlaouen I, Cau M, F&#x000e9;rec C, Melis MA. Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:685–7.</span> [<a href="/pmc/articles/PMC2857203/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2857203</span></a>] [<a href="/pubmed/20007136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20007136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.lebr_n.1998.111">Lebr&#x000f3;n JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">93</span>:111–23.</span> [<a href="/pubmed/9546397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9546397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.mart_nez.2011.325">Mart&#x000ed;nez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>:325–35.</span> [<a href="/pubmed/21254180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21254180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.mclaren.2015.429">McLaren CE, Emond MJ, Subramaniam VN, Phatak PD, Barton JC, Adams PC, Goh JB, McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm GA, Anderson GJ, McLaren GD. Exome sequencing in <em>HFE</em> C282Y homozygous men with extreme phenotypes identifies a <em>GNPAT</em> variant associated with severe iron overload. <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">62</span>:429–39.</span> [<a href="/pmc/articles/PMC4508230/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4508230</span></a>] [<a href="/pubmed/25605615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25605615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.mclaren.1998.543">McLaren CE, McLachlan GJ, Halliday JW, Webb SI, Leggett BA, Jazwinska EC, Crawford DH, Gordeuk VR, McLaren GD, Powell LW. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. <span><span class="ref-journal">Gastroenterology. </span>1998;<span class="ref-vol">114</span>:543–9.</span> [<a href="/pubmed/9496946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9496946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.morrison.2003.627">Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. <span><span class="ref-journal">Ann Intern Med. </span>2003;<span class="ref-vol">138</span>:627–33.</span> [<a href="/pubmed/12693884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12693884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.ong.2017.e607">Ong SY, Gurrin LC, Dolling L, Dixon J, Nicoll AJ, Wolthuizen M, Wood EM, Anderson GJ, Ramm GA, Allen KJ, Olynyk JK, Crawford D, Ramm LE, Gow P, Durrant S, Powell LW, Delatycki MB. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. <span><span class="ref-journal">Lancet Haematol. </span>2017;<span class="ref-vol">4</span>:e607–e614.</span> [<a href="/pubmed/29195602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29195602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.pedersen.2009.775">Pedersen P, Milman N. Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. <span><span class="ref-journal">Ann Hematol. </span>2009;<span class="ref-vol">88</span>:775–84.</span> [<a href="/pubmed/19159930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19159930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.phatak.2008.270">Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. <span><span class="ref-journal">Ann Intern Med. </span>2008;<span class="ref-vol">149</span>:270–2.</span> [<a href="/pubmed/18711158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18711158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.phatak.2010.1671">Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:1671–9.</span> [<a href="/pmc/articles/PMC3034044/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3034044</span></a>] [<a href="/pubmed/20814896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20814896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.piperno.2000.441">Piperno A, Arosio C, Fossati L, Vigan&#x000f2; M, Trombini P, Vergani A, Mancia G. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. <span><span class="ref-journal">Gastroenterology. </span>2000;<span class="ref-vol">119</span>:441–5.</span> [<a href="/pubmed/10930379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10930379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.ptaszek.2005.689">Ptaszek LM, Price ET, Hu MY, Yang PC. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. <span><span class="ref-journal">J Cardiovasc Magn Reson. </span>2005;<span class="ref-vol">7</span>:689–92.</span> [<a href="/pubmed/16136860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16136860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.ramazzotti.2009.62">Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, Luciani A, Midiri M, Sallustio G, Valeri G, Caruso V, Centra M, Cianciulli P, De Sanctis V, Maggio A, Lombardi M. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. <span><span class="ref-journal">J Magn Reson Imaging. </span>2009;<span class="ref-vol">30</span>:62–8.</span> [<a href="/pubmed/19557847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19557847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.saddi.1978.41">Saddi R, Feingold J, Degrese CH, Fagard R. Desferrioxamine utilisation for the quantitation of iron excess. Study of 24 patients having idiopathic haemochromatosis. <span><span class="ref-journal">Biomedicine. </span>1978;<span class="ref-vol">28</span>:41–7.</span> [<a href="/pubmed/667275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 667275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.scotet.2003.129">Scotet V, Merour MC, Mercier AY, Chanu B, Le Faou T, Raguenes O, Le Gac G, Mura C, Nousbaum JB, Ferec C. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. <span><span class="ref-journal">Am J Epidemiol. </span>2003;<span class="ref-vol">158</span>:129–34.</span> [<a href="/pubmed/12851225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12851225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.st_pierre.2005.855">St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:855–61.</span> [<a href="/pubmed/15256427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15256427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.swinkels.2007.452">Swinkels DW, Jorna AT, Raymakers RA. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. <span><span class="ref-journal">Neth J Med. </span>2007;<span class="ref-vol">65</span>:452–5.</span> [<a href="/pubmed/18079569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18079569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.tavill.2001.1321">Tavill AS. Diagnosis and management of hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2001;<span class="ref-vol">33</span>:1321–8.</span> [<a href="/pubmed/11343262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11343262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.tsochatzis.2011.650">Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughts AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. <span><span class="ref-journal">J Hepatol. </span>2011;<span class="ref-vol">54</span>:650–9.</span> [<a href="/pubmed/21146892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21146892</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.vanclooster.2015.205">Vanclooster A, Cassiman D, Van Steenbergen W, Swinkels DW, Janssen MC, Drenth JP, Aertgeerts B, Wollersheim H. The quality of hereditary haemochromatosis guidelines: a comparative analysis. <span><span class="ref-journal">Clin Res Hepatol Gastroenterol. </span>2015;<span class="ref-vol">39</span>:205–14.</span> [<a href="/pubmed/25441394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25441394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.whitington.2018.218">Whitington PF, Kelly S, Taylor SA, N&#x000f3;brega S, Schreiber RA, Sokal EM, Hibbard JU. Antenatal treatment with intravenous immunoglobulin to prevent gestational alloimmune liver disease: comparative effectiveness of 14-week versus 18-week initiation. <span><span class="ref-journal">Fetal Diagn Ther. </span>2018;<span class="ref-vol">43</span>:218–25.</span> [<a href="/pubmed/28787718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28787718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.whitlock.2006.209">Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. <span><span class="ref-journal">Ann Intern Med. </span>2006;<span class="ref-vol">145</span>:209–23.</span> [<a href="/pubmed/16880463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16880463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hemochromatosis.REF.yamashita.2003.388">Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2003;<span class="ref-vol">1</span>:388–91.</span> [<a href="/pubmed/15017658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15017658</span></a>]</div></li></ul></div></div><div id="hemochromatosis.Chapter_Notes"><h2 id="_hemochromatosis_Chapter_Notes_">Chapter Notes</h2><div id="hemochromatosis.Author_History"><h3>Author History</h3><p>James C Barton, MD (2018-present)<br />Robin L Bennett, MS; University of Washington (2000-2015)<br />Corwin Q Edwards, MD (2018-present)<br />Kris V Kowdley, MD; Virginia Mason Medical Center (2000-2015)<br />Arno G Motulsky, MD; University of Washington (2000-2015)<br />Lawrie Powell, AC, MD, PhD; Royal Brisbane &#x00026; Women's Hospital (2015-2018)<br />Rebecca Seckington; University of Queensland (2015-2018)<br />Jonathan F Tait, MD, PhD; University of Washington School of Medicine (2000-2011)</p></div><div id="hemochromatosis.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>6 December 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 September 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 April 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 December 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 July 2005 (kk) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> clinically available</div></li><li class="half_rhythm"><div>13 September 2004 (kk) Author revisions</div></li><li class="half_rhythm"><div>7 October 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 April 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>October 1998 (kk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1440</span><span class="label">PMID: <a href="/pubmed/20301613" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301613</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gcps/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/carasil/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1440&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1440/?report=reader">PubReader</a></li><li><a href="/books/NBK1440/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1440" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1440" style="display:none" title="Cite this Page"><div class="bk_tt">Barton JC, Edwards CQ. HFE Hemochromatosis. 2000 Apr 3 [Updated 2018 Dec 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1440/pdf/Bookshelf_NBK1440.pdf">PDF version of this page</a> (739K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hemochromatosis.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hemochromatosis.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hemochromatosis.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hemochromatosis.Genetically_Related_Alle" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hemochromatosis.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hemochromatosis.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hemochromatosis.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hemochromatosis.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hemochromatosis.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hemochromatosis.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hemochromatosis.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=650[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BMP2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3077[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HFE</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1475938" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1475938" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1475938" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1475938" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301349" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Hereditary Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Hereditary Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Goldberg YP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301523" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TFR2</i>-Related Hereditary Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">TFR2</i>-Related Hereditary Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">De Gobbi M, Roetto A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26365338" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network.</a><span class="source">[Am J Hum Genet. 2015]</span><div class="brieflinkpop offscreen_noflow">Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gallego CJ, Burt A, Sundaresan AS, Ye Z, Shaw C, Crosslin DR, Crane PK, Fullerton SM, Hansen K, Carrell D, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Hum Genet. 2015 Oct 1; 97(4):512-20. Epub 2015 Sep 10.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23418762" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemochromatosis.</a><span class="source">[Am Fam Physician. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemochromatosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Crownover BK, Covey CJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am Fam Physician. 2013 Feb 1; 87(3):183-90. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16871764" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Molecular genetic diagnostics and screening of hereditary hemochromatosis].</a><span class="source">[Vnitr Lek. 2006]</span><div class="brieflinkpop offscreen_noflow">[Molecular genetic diagnostics and screening of hereditary hemochromatosis].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zlocha J, Kovács L, Pozgayová S, Kupcová V, Durínová S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Vnitr Lek. 2006 Jun; 52(6):602-8. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301613" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301613" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c5ddde0891169409bc7">HFE Hemochromatosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">HFE Hemochromatosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:26:53-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88D7B7E03FC1C1000000000629023F&amp;ncbi_session=CE88D7B7E040C5C1_1577SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1440%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1440&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1440/&amp;ncbi_pagename=HFE Hemochromatosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88D7B7E040C5C1_1577SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>